Summary
SARCLISA ESCENA is the first anticancer treatment approved for delivery via an on-body injector — approved in the US, EU, and UK.
It's delivered via CirCLIQ, a hands-free wearable device built on Enable Injections' enFuse platform.
Approval was supported by the Phase 3 IRAKLIA trial, showing efficacy, safety, and pharmacokinetics comparable to IV SARCLISA, with less time in treatment and fewer infusion reactions.
The approval strengthens Sanofi's competitive footing against DARZALEX and reflects a broader shift toward take-home, low-burden cancer care.
For decades, cancer treatment has meant one thing for most patients: the infusion chair. Hou...
